scispace - formally typeset
P

Pierre Ernst

Researcher at McGill University

Publications -  241
Citations -  17884

Pierre Ernst is an academic researcher from McGill University. The author has contributed to research in topics: Asthma & COPD. The author has an hindex of 64, co-authored 232 publications receiving 16614 citations. Previous affiliations of Pierre Ernst include Jewish General Hospital & McGill University Health Centre.

Papers
More filters
Journal ArticleDOI

Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?

TL;DR: An increasing dose-response relationship between the regular use of beta-agonist inhalers and the risk of asthma death and near death among a cohort of 12,301 subjects who had been dispensed 10 or more prescriptions of asthma drugs from January 1980 to April 1987 is reported.
Journal ArticleDOI

Low-dose inhaled and nasal corticosteroid use and the risk of cataracts.

TL;DR: It is concluded that, among the elderly, even low doses of inhaled corticosteroids are associated with a small but significant excess risk of cataracts requiring extraction, and the increase in risk was apparent even at daily doses of ≤500 μg.
Journal Article

Canadian pediatric asthma consensus guidelines, 2003 (updated to december 2004)

TL;DR: This guide for asthma management is based on the best available published data and the opinion of health care professionals including asthma experts and educators and generally support previous recommendations and focus on new issues, particularly those relevant to children and their families.
Journal ArticleDOI

Inhaled Corticosteroids and Risk of Tuberculosis in Patients with Respiratory Diseases

TL;DR: Exposure to ICS is not associated with risk of TB in the presence of OCS but is associated with increased TB risk in nonusers of O CS, and among users of EMT, no significant relationship could be demonstrated.
Journal ArticleDOI

Risks of pneumonia in patients with asthma taking inhaled corticosteroids.

TL;DR: There is no increased risk of pneumonia in patients with asthma, identified as an AE or SAE, in clinical trials using budesonide, and the relative effect of ICS on pneumonia adverse events (AEs) or serious adverse Events (SAEs) was estimated.